Tilray Brands continues to advance its diversification strategy and reports progress in two key markets. While sales of the alcohol division are being expanded in the USA, the pharmaceutical business is in the spotlight in Germany. These operational steps are intended to support growth, after the international segment in particular has recently been convincing.
Award for German daughter
The group’s European pharmaceutical sales subsidiary, CC Pharma, was yesterday recognized as a “TOP 100 Innovator” in Germany. CC Pharma is a central component of Tilray’s medical cannabis strategy and supplies a network of over 13,000 pharmacies nationwide. The recognition underlines the relevance of the German infrastructure for the Canadian company, which is increasingly focusing on European markets.
At the same time, Tilray announced an expansion in the alcoholic beverages segment. The Breckenridge Distillery, which is part of the group, has signed Romano Beverage as its new sales partner for the state of Illinois. This move aims to increase the market presence of the spirits portfolio in the US and further diversify revenue streams beyond the core cannabis business.
Advertisement
Should investors sell immediately? Or is it worth joining? Tilray?
Strong international dynamics
The current operational reports confirm the trend that was already apparent in the financial figures from January 8th. In the second quarter of fiscal 2026, Tilray posted record net sales, with its international cannabis business particularly standing out with an increase of 36 percent. In this context, management also confirmed the forecast for adjusted EBITDA for the current financial year.
The next important milestone for investors is the quarterly report, which is expected to be published in April 2026. It will then become clear to what extent the new sales structures in the USA and the positioning in Germany help to keep the growth rates in the beverage and wellness sector stable.
Tilray Stock: Buy or Sell?! New Tilray analysis from February 6 provides the answer:
The latest Tilray figures speak for themselves: there is an urgent need for action for Tilray shareholders. Is it worth getting started or should you sell? In the current free analysis from February 6th you will find out what to do now.
Tilray: Buy or Sell? Read more here…
